We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

230 hedge funds and large institutions have $3.57B invested in Amicus Therapeutics in 2022 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 91 increasing their positions, 64 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 64

27% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 33

22% more call options, than puts

Call options by funds: $8.86M | Put options by funds: $7.25M

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

11% more capital invested

Capital invested by funds: $3.2B → $3.57B (+$367M)

4% more funds holding

Funds holding: 222230 (+8)

5.45% less ownership

Funds ownership: 109.55%104.1% (-5.5%)

Holders
230
Holders Change
+8
Holders Change %
+3.6%
% of All Funds
3.7%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.11%
New
42
Increased
91
Reduced
64
Closed
33
Calls
$8.86M
Puts
$7.25M
Net Calls
+$1.61M
Net Calls Change
-$1.44M
Name Holding Trade Value Shares
Change
Change in
Stake
SAM
51
Sectoral Asset Management
Quebec, Canada
$6.2M -$732K -65,000 -11%
Millennium Management
52
Millennium Management
New York
$5.75M +$4.74M +420,898 +847%
CM
53
CM Management
Florida
$5.5M
Barclays
54
Barclays
United Kingdom
$5.15M +$183K +16,299 +4%
SVCM
55
Saturn V Capital Management
Texas
$4.89M +$6.37M +566,179 New
MB
56
MPM BioImpact
Massachusetts
$4.89M +$84K +7,464 +2%
HIM
57
Hillsdale Investment Management
Ontario, Canada
$4.89M +$4.5M +400,100 New
RhumbLine Advisers
58
RhumbLine Advisers
Massachusetts
$4.8M +$236K +20,970 +6%
Citigroup
59
Citigroup
New York
$4.6M -$2.74M -243,325 -39%
Legal & General Group
60
Legal & General Group
United Kingdom
$4.29M +$352K +31,225 +10%
Ameriprise
61
Ameriprise
Minnesota
$4.09M -$74.5K -6,620 -2%
IHAM
62
Integral Health Asset Management
New York
$3.99M +$2.22M +197,000 +152%
Prudential Financial
63
Prudential Financial
New Jersey
$3.98M +$1.7M +150,985 +86%
AllianceBernstein
64
AllianceBernstein
Tennessee
$3.86M +$13.5K +1,200 +0.4%
FA
65
Faithward Advisors
Pennsylvania
$3.86M -$4.65K -413 -0.1%
SEI Investments
66
SEI Investments
Pennsylvania
$3.83M -$1.01M -89,368 -22%
Neuberger Berman Group
67
Neuberger Berman Group
New York
$3.79M -$1.83M -162,158 -34%
California State Teachers Retirement System (CalSTRS)
68
California State Teachers Retirement System (CalSTRS)
California
$3.58M +$38.7K +3,439 +1%
Man Group
69
Man Group
United Kingdom
$3.55M +$2.09M +185,635 +177%
HF
70
HRT Financial
New York
$3.55M +$2.69M +238,531 +457%
Bank of Montreal
71
Bank of Montreal
Ontario, Canada
$3.55M -$12.3K -1,094 -0.4%
Royal Bank of Canada
72
Royal Bank of Canada
Ontario, Canada
$3.48M +$1.02M +90,969 +47%
AG
73
Algert Global
California
$3.4M +$703K +62,440 +29%
CS
74
Credit Suisse
Switzerland
$3.37M +$74.4K +6,606 +2%
UBS AM
75
UBS AM
Illinois
$3.05M +$324K +28,777 +13%

FOLD Hedge Fund Activity: Q4 2022 in Review

230 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2022, worth a combined $3.57B — up 11% from $3.2B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new FOLD positions and 33 closed out — a net gain of 9 holders — while 91 added to existing stakes and 64 trimmed.

The largest buyer was Pictet Asset Management (Switzerland), adding an estimated $55.7M. The largest seller was Janus Henderson Group, cutting an estimated $179M.

  • 230 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2022, up from 222 in Q3 2022.
  • Funds reported $3.57B of Amicus Therapeutics stock for Q4 2022, up 11% quarter-over-quarter.
  • 42 funds opened new Amicus Therapeutics positions in Q4 2022 and 33 closed out, a net change of +9 holders.
  • The largest Amicus Therapeutics buyer in Q4 2022 was Pictet Asset Management (Switzerland), an estimated $55.7M added.
  • The largest Amicus Therapeutics seller in Q4 2022 was Janus Henderson Group, an estimated $179M sold.

Based on aggregated 13F filings for Q4 2022.